NCT04194697已完成不适用
A Study to Assess Effect of Exercise Program Provided by Smartphone Application on the Body Composition
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Change from baseline in body fat ratio
研究概览
简要总结
The primary objective of this study is to explore the effect of an exercise program combining aerobic and resistance exercises provided by mobile healthcare applications (hereinafter referred to as "app") on the body composition in app-using exercise group compared to non-exercise group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who can perform a 12-week exercise program using the specified app during the study in Japan if they are assigned to the app-using exercise group.
- •Subjects who agree to perform a 12-week exercise program using the app during the period specified in the protocol and not to change activities/exercise of daily living compared with before participation in the study except for the exercise program using the app if they are assigned to the app-using exercise group, or subjects who agree not to change activities/exercise of daily living compared with before participation in the study during the period specified in the protocol if they are assigned to the non-exercise group.
- •Subjects with body mass index (BMI) of 25.0 kg/m^2 or more and less than 30.0 kg/m^2 at screening and baseline
- •Subjects with waist circumferences meeting the following at screening and baseline. Male: 85 cm or more, Female: 90 cm or more
- •Female subject who applied to one of the following
- •Subjects who are postmenopausal (without a menstrual period for at least 1 year) at the time of informed consent.
- •Subjects of non-childbearing potential due to undergoing surgery.
- •Females of childbearing potential who agree to use contraception during the participation in the study and have a negative pregnancy test at screening and baseline.
- •Subjects who agree not to participate in clinical studies of drugs, regenerative medicine products, or medical devices, post-marketing clinical studies, or clinical research (including studies that do not use drugs, regenerative medicine products, or medical devices as with this study) other than this study after providing informed consent until the completion of the examination/observation at Week 12.
排除标准
- •Subjects who regularly perform at least 1 session of exercise per week for at least 30 minutes per session on average other than activities of daily living during 6 months before providing informed consent.
- •Subjects who receive treatment for obesity on an outpatient basis at the time of informed consent or plan to start treatment for obesity on an outpatient basis during the period until the completion of the examination/observation at Week
- •Subjects whose systolic blood pressure (sitting position at rest) is 160 mmHg or more or whose diastolic blood pressure (sitting position at rest) is 100 mmHg or more at screening or baseline.
- •Subjects with concomitant uncontrolled hypertension or concomitant hypertension that is considered likely to be exacerbated by the exercise intervention.
- •Subjects with previous or concomitant severe heart diseases (ischemic heart disease, myocardial infarction, congestive heart failure, angina pectoris, and arrhythmia requiring treatment with β-blockers and other drugs, etc.).
- •Subjects with previous or concomitant cerebrovascular disorders (cerebral infarction, transient cerebral ischemia, etc.).
- •Subjects with fasting blood glucose of 250 mg/dL or more or with positive urinary ketone bodies at screening.
- •Subjects with concomitant uncontrolled diabetes or with diabetic complications (diabetic neuropathy, diabetic nephropathy, and diabetic retinopathy excluding simple retinopathy).
- •Subjects with concomitant retinal neovascular lesions (exudative age-related macular degeneration, retinal vein occlusion, etc.) or concomitant retinopathy occurring within 6 months after laser photocoagulation.
- •Subjects with previous or concomitant arteriosclerosis obliterans of lower extremities
- •Subjects with concomitant motor disorders.
- •Subjects with concomitant severe respiratory diseases.
- •Subjects with concomitant severe liver diseases (viral hepatitis, drug-induced liver injury, etc.).
- •Subjects with concomitant severe renal diseases (acute renal failure, glomerulonephritis, interstitial nephritis, etc.).
- •Subjects with previous or concomitant malignancies. However, subjects are allowed to be enrolled if they have experienced no recurrence without the need for treatment within 5 years before providing informed consent.
- •Subjects with previous or concomitant schizophrenia, psychiatric disorders such as bipolar disorder or major depressive disorder, or dementia.
- •Subjects who are taking any of the following drugs at the time of informed consent: insulin preparations, sulfonyl urea hypoglycemic agents, short-acting insulin secretagogues (glinide), Glucagon-like peptide (GLP)-1 receptor agonists, biguanides, thiazolidines, Sodium-glucose co-transporter (SGLT)2 inhibitors, and anti-obesity drugs, or subjects who plan to receive any of these drugs during the period until the completion of the examination/observation at Week
- •Subjects who are taking any of the following at the time of informed consent: antidyslipidemic agents or drugs affecting lipid metabolism, supplements, and health foods (including foods for specified health use and foods with functional claims), or subjects who plan to take any of these during the period until the completion of the examination/observation at Week
- •However, subjects are allowed to take these drugs, supplements, or foods if they can take them with a stable dosage from at least 28 days before baseline until the completion of the examination/observation at Week
- •Subjects who have metal placed by lumbar spinal surgery and other surgery at the site where abdominal CT scan is performed.
- •Subjects with implantable medical devices such as cardiac pacemakers and implantable defibrillators.
- •Subjects who have participated or are participating in clinical studies of other drugs, regenerative medicine products, or medical devices, post-marketing clinical studies, or clinical research (including studies that do not use drugs, regenerative medicine products, or medical devices as with this study) within 12 weeks (84 days) before screening.
- •Subjects who are employed by the research implementing entity of this study or institutions/organizations related to this study.
- •Subjects who are considered ineligible for the participation in this study.
结局指标
主要结局
Change from baseline in body fat ratio
时间窗: Baseline and Week 12
Total fat ratio will be derived from body composition analyzer.
Change from baseline in visceral fat area
时间窗: Baseline and Week 12
Visceral fat area will be measured with computed tomography (CT).
次要结局
- Change from baseline in subcutaneous fat area(Baseline and Week 12)
- Change from baseline in body weight(Baseline and Week 12)
- Change from baseline in total fat area(Baseline and Week 12)
- Change from baseline in muscle mass(Baseline and Week 12)
- Change from baseline in waist circumference(Baseline and Week 12)
- Number of participants with Adverse Events (AEs)(Up to Week 12)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effects of an Exercise Program Among CF Patients With DysglycemiaCystic Fibrosis Related DiabetesCystic FibrosisNCT02127957Institut de Recherches Cliniques de Montreal18
已完成
不适用
Exercise to Improve Outcomes of Treatment for Methamphetamine UsersAddictionNCT01103531University of California, Los Angeles135
已完成
不适用
Effects of Exercise Intervention on Insulin Levels in Breast Cancer SurvivorsBreast CancerNCT00153894Dana-Farber Cancer Institute100
已完成
不适用
The Effects of Aerobic Exercise in Patients With Ankylosing SpondylitisAerobic ExerciseDisease ActivityAnkylosing SpondylitisNCT05968469Afyonkarahisar Health Sciences University56
招募中
不适用
Aerobic Training and Diet on the Immune System in Postmastectomy Patients Receiving ChemotherapyImmune DeficiencyDiet, HealthyBreast CancerNCT05605808Cairo University60